Key Stats for ISRG Stock
- Past week’s performance: +3.6%
- 52-week range: $428 to $604
- Valuation model target price: $652
- Implied upside: 36.2% over 2.7 years
Value your favorite stocks like ISRG with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Intuitive Surgical (ISRG) stock moved higher this week after the company reported a strong first-quarter earnings beat. Revenue rose 23% year over year to $2.77 billion, driven by higher procedure volume, more da Vinci system placements, and growth in the installed base. The da Vinci system is Intuitive’s robotic surgery platform, while Ion is used for minimally invasive lung biopsy procedures.
The company placed 431 da Vinci systems in Q1, up from 367 a year ago. That included 232 da Vinci 5 systems, showing continued adoption of the newest platform. Instruments and accessories revenue also rose 23% to $1.69 billion, which matters because this recurring revenue grows as installed robots are used more often.
Investors also reacted positively to higher 2026 procedure guidance. Intuitive now expects worldwide da Vinci procedure growth of 13.5% to 15.5% in 2026, slightly above its prior outlook. Management said Q1 performance reflected “expanded adoption of our da Vinci, Ion, and digital platforms.”
The rally helped offset some earlier pressure from regulatory concerns. In March, the FDA said Intuitive reported four serious injuries and one death tied to a surgical stapler issue. That kept investors focused on product safety and regulatory risk, even as the earnings report showed strong demand.
See analysts’ growth forecasts and price targets for ISRG (It’s free) >>>
Is ISRG Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): 14.2%
- Operating Margins: 37.4%
- Exit P/E Multiple: 45x
Based on these inputs, the model estimates a target price of $653, implying 36.2% total upside from the current share price of $479 and an annualized return of 12.2% over the next 2.7 years.
ISRG still trades at a premium valuation, with a 45.2x forward P/E and 30.9x forward EV/EBITDA. That premium reflects its leadership in robotic-assisted surgery, strong margins, and recurring revenue from procedures. The stock does not look cheap, but the model suggests returns can still be attractive if growth holds.
The valuation depends on procedure growth continuing across da Vinci and Ion. LTM gross margin is 66.3%, while LTM EBIT margin is 30.5%. These margins show that incremental procedure volume can support earnings growth as the installed base expands.
The balance sheet also supports the premium. Intuitive has net cash of about $4.5 billion and no meaningful net debt. That gives the company flexibility for buybacks, product investment, and global expansion.
Compared with its own history, the forecast assumes a lower exit P/E than the 5-year historical level of 57.4x. That makes the valuation less aggressive than past trading levels, but still dependent on strong execution.
What’s Driving ISRG Stock Going Forward?
Procedure growth remains the most important driver. More surgeries on da Vinci systems increase demand for instruments, accessories, and services. This creates recurring revenue after each robot is installed.
The da Vinci 5 rollout is another key catalyst. Intuitive placed 232 da Vinci 5 systems in Q1, up from 147 a year earlier. Continued adoption could support systems revenue and deepen hospital relationships.
Margins will also matter because tariffs are now part of the outlook. Intuitive expects 2026 non-GAAP gross margin of 67.5% to 68.5%, including a 1.0% revenue impact from tariffs. If tariffs rise beyond current assumptions, management said the financial impact could be material.
Investors will also watch the April 30 annual meeting and the expected Q2 report in July. The main questions are whether procedure growth stays strong, whether da Vinci 5 placements keep accelerating, and whether regulatory concerns remain contained. Those factors should drive the next major move in ISRG stock.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Intuitive Surgical?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ISRG, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track ISRG alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Intuitive Surgical stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
